Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-BCMA/CS1 in relapsed/refractory multiple myeloma
NCT05950113Phase 1Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CS1 cCAR in multiple myeloma (MM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Dose Limiting Toxicities at 28 days. Planned start Mar 2024; status: withdrawn.
02
Drugs
BCMA-CS1 cCAR
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05950113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950113.